Drugs / Sacubitril/valsartan
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05089539 | Nov 2021 → Feb 2022 | diastolic heart failure | Chongqing Medical University | Unknown | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Sacubitril/valsartan | “Sacubitril/valsartan \[100 mg\] bid). Continuous treatment was maintained for at least three months.” NCT05089539 ↗ |